Patients diagnosed with a glioblastoma, and who undergo current standard treatment, have a median survival of 16 months. Based on recent information on the mechanisms of chemotherapy, a team of researchers developed a new clinical approach overcome treatment resistance that increased the median survival to 22 months — bringing much needed hope to those affected by this aggressive disease.